Home / Antiviral

Antiviral peptides

Block the virus at the surface, with a peptide rather than an antibody.

Antiviral

Peptides that bind the virus and block entry

No approved drug exists for the treatment of COVID-19 patients outside the hospital setting. Repurposed drugs have shown some clinical benefit, but they have limitations, and are not approved to treat COVID-19 patients who are not hospitalized.

We are developing rapidly scalable, cost-effective technology which blocks COVID-19 infection by “binding” or attaching specifically to SARS-CoV-2 and blocking its entry into human cells. We believe the peptides (small proteins) we are studying act like antibodies or complements that our body naturally produces — binding to the SARS-CoV-2 virus, and targeting it for destruction.

Colourised electron micrograph of SARS-CoV-2 virus particles
SARS-CoV-2 particles. NIAID-RML, CC BY 2.0. Illustration, not company data.

The award

An NSF STTR Phase I

The project was supported by a Small Business Technology Transfer Phase I award from the National Science Foundation, to study how self-assembled peptides assemble on the surface of pathogens such as SARS-CoV-2 and what that does to infectivity and immune recognition.

We hope to create a safe and inexpensive therapeutic that will help reduce the spread and increase accessibility of treatment for COVID-19.

As awarded

  • ProgrammeNSF STTR Phase I
  • Award year2021
  • Amount$255,933
  • Contract2032392
  • ProjectSelf-assembled peptides against SARS-CoV-2
  • Principal investigatorCorey Heffernan
  • Company statusHUBZone owned; socially and economically disadvantaged

The paper

Antiviral fibrils of self-assembled peptides with tunable compositions

Nature Communications, 7 February 2024

“The lasting threat of viral pandemics necessitates the development of tailorable first-response antivirals with specific but adaptive architectures for treatment of novel viral infections. Here, such an antiviral platform has been developed based on a mixture of hetero-peptides self-assembled into functionalized β-sheets capable of specific multivalent binding to viral protein complexes.”

Work with us

Protein-based therapeutics, translated

Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.